V0132529
Elevidys
:
Orð- og myndmerki:
1759804:
Skráð:
23.05.2023:
15.12.2024:
15.2.2025:
15.2.2025:
26.11.12, 26.11.25, 26.15.25, 27.05.01, 27.05.08, 27.05.17:
The mark consists of three alternately-shaded semi-circles increasing in size to an oval center and three alternately-shaded semi-circles decreasing in size on the other side of the oval center and followed by 'Elevidys.' The color gray is intended to show shading or contrast only.
:
Sarepta Therapeutics, Inc.:
215 First Street, Cambridge MA 02142, US
:
97925396:
8.5.2023:
Bandaríkjunum
- 5
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; pharmaceutical preparations that modulate rna expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals; pharmaceutical preparations for gene therapy, gene editing, and genome editing; gene therapy products for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases.
- 41
Medical training and teaching.
- 44
Medical services; providing health information.